It was a historical month in the field of immuno-oncology and the biopharma industry in general. Last month, we’ve seen back-to-back news about CAR-T therapy, from Gilead Science’s $ 11.9 Billion acquisition of Kite Pharma to the approval of the first CAR-T therapy in the world from Novartis. Meanwhile, we have seen several articles […]